DB:3G6

Stock Analysis Report

Executive Summary

GNI Group Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally.


Snowflake Analysis

Excellent balance sheet with acceptable track record.

Share Price & News

How has GNI Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 3G6's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-2.9%

3G6

-0.7%

DE Biotechs

-0.6%

DE Market


1 Year Return

32.6%

3G6

-13.5%

DE Biotechs

-20.9%

DE Market

Return vs Industry: 3G6 exceeded the German Biotechs industry which returned -13.2% over the past year.

Return vs Market: 3G6 exceeded the German Market which returned -20.9% over the past year.


Shareholder returns

3G6IndustryMarket
7 Day-2.9%-0.7%-0.6%
30 Day-3.8%-7.8%-16.6%
90 Day-44.0%-21.1%-26.0%
1 Year32.6%32.6%-13.3%-13.5%-18.6%-20.9%
3 Year-56.4%-56.4%14.1%12.9%-19.0%-25.8%
5 Year44.5%44.5%-9.6%-11.9%-21.1%-31.8%

Price Volatility Vs. Market

How volatile is GNI Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is GNI Group undervalued compared to its fair value and its price relative to the market?

285.8x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 3G6's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 3G6's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 3G6 is poor value based on its PE Ratio (259.9x) compared to the Biotechs industry average (40.7x).

PE vs Market: 3G6 is poor value based on its PE Ratio (259.9x) compared to the German market (16.6x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 3G6's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 3G6 is overvalued based on its PB Ratio (4.5x) compared to the DE Biotechs industry average (3.3x).


Next Steps

Future Growth

How is GNI Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

55.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as GNI Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has GNI Group performed over the past 5 years?

45.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 3G6 has high quality earnings.

Growing Profit Margin: 3G6 became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: 3G6 has become profitable over the past 5 years, growing earnings by 45.4% per year.

Accelerating Growth: 3G6 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 3G6 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (16.1%).


Return on Equity

High ROE: 3G6's Return on Equity (4.8%) is considered low.


Next Steps

Financial Health

How is GNI Group's financial position?


Financial Position Analysis

Short Term Liabilities: 3G6's short term assets (¥10.2B) exceed its short term liabilities (¥3.2B).

Long Term Liabilities: 3G6's short term assets (¥10.2B) exceed its long term liabilities (¥4.3B).


Debt to Equity History and Analysis

Debt Level: 3G6's debt to equity ratio (12.8%) is considered satisfactory.

Reducing Debt: 3G6's debt to equity ratio has increased from 8.8% to 12.8% over the past 5 years.


Balance Sheet

Inventory Level: 3G6 has a low level of unsold assets or inventory.

Debt Coverage by Assets: 3G6's debt is covered by short term assets (assets are 6.1x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 3G6 is profitable, therefore cash runway is not a concern.

Forecast Cash Runway: 3G6 is profitable, therefore cash runway is not a concern.


Next Steps

Dividend

What is GNI Group's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 3G6's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 3G6's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 3G6's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 3G6's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 3G6's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

19.3yrs

Average management tenure


CEO

Ying Luo (54yo)

10.83s

Tenure

Dr. Ying Luo, Ph.D. is Chairman, Chief Executive Officer and President of Cullgen Inc. Dr. Luo has been the Chief Executive Officer, President and Representative Executive Officer of GNI Group Ltd. since J ...


Leadership Team

NamePositionTenureCompensationOwnership
Ying Luo
CEO, President10.83yrsno data3.27% ¥14.8m
Kosuke Tashiro
Co-Founder19.25yrsno datano data
Cristin Print
Co-Founder19.25yrsno datano data
Stephen Charnock-Jones
Co-Founder19.25yrsno datano data
Thomas Eastling
CFO, Representative Executive Officer & Director7.08yrsno data0.0048% ¥22.0k
Hiroyuki Sato
Executive Officer & Directorno datano data0.0097% ¥43.9k

19.3yrs

Average Tenure

60yo

Average Age

Experienced Management: 3G6's management team is seasoned and experienced (19.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.3%.


Top Shareholders

Company Information

GNI Group Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: GNI Group Ltd.
  • Ticker: 3G6
  • Exchange: DB
  • Founded: 2001
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: JP¥53.127b
  • Listing Market Cap: JP¥453.808m
  • Shares outstanding: 43.40m
  • Website: https://www.gnipharma.com

Number of Employees


Location

  • GNI Group Ltd.
  • Nihonbashi-Honcho YS Building
  • 3rd Floor
  • Tokyo
  • 103-0023
  • Japan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
2160TSE (The Tokyo Stock Exchange)YesCommon StockJPJPYAug 2007
3G6DB (Deutsche Boerse AG)YesCommon StockDEEURAug 2007
GNII.FOTCPK (Pink Sheets LLC)YesCommon StockUSUSDAug 2007

Biography

GNI Group Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is Phase II clinical trial for the treatment of liver fibrosis, as well as F573, which is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was founded in 2001 and is headquartered in Tokyo, Japan. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/07 00:49
End of Day Share Price2020/04/06 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.